Brent Hatzis-Schoch - May 12, 2021 Form 4 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)

Role
Chief Operating Officer and General Counsel
Signature
/s/ Brent Hatzis-Schoch
Stock symbol
BDTX
Transactions as of
May 12, 2021
Transactions value $
-$98,755
Form type
4
Date filed
5/13/2021, 04:53 PM
Next filing
Feb 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BDTX Common Stock Options Exercise $13K +4.08K +48.55% $3.20 12.5K May 12, 2021 Direct
transaction BDTX Common Stock Sale -$30.3K -1.16K -9.3% $26.11* 11.3K May 12, 2021 Direct F1, F2
transaction BDTX Common Stock Sale -$71.6K -2.57K -22.67% $27.90* 8.75K May 12, 2021 Direct F1, F3
transaction BDTX Common Stock Sale -$9.9K -351 -4.01% $28.20* 8.4K May 12, 2021 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BDTX Stock Option (Right to Buy) Options Exercise $0 -4.08K -2.48% $0.00 160K May 12, 2021 Common Stock 4.08K $3.20 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.81 to $26.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.095 to $28.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.12 to $28.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter.

Remarks:

Chief Operating Officer and General Counsel